Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Non-Hodgkin

Explore clinical trials studying Lymphoma, Non-Hodgkin. Study availability and eligibility vary by location and protocol.

228 public trials 23 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Non-Hodgkin trial results

Completed

A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

NCT03900598

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +15 more
Locations
  • City of Hope Duarte, California, United States
  • University of Nebraska Medical Center Omaha, Nebraska, United States
  • Weill Cornell Medicine New York, United States
  • Icahn School of Medicine at Mount Sinai New York, United States
View all 47 locations
View Trial Details
Completed

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

NCT03744676

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Local Institution - 0057 Los Angeles, California, United States
  • Local Institution - 0060 Denver, Colorado, United States
  • Local Institution - 0089 Miami, Florida, United States
  • Local Institution - 0081 Orlando, Florida, United States
View all 23 locations
View Trial Details
Completed

A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)

NCT05844956

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations
  • Research Site Beijing, Beijing Municipality, China
  • Research Site Beijing, Beijing Municipality, China
  • Research Site Guangzhou, Guangdong, China
  • Research Site Zhengzhou, Henan, China
View Trial Details
Completed

Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients

NCT03366272

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations
  • Landeskrankenhaus Feldkirch Feldkirch, Austria
  • Innsbruck University Hospital Innsbruck, Austria
  • Kepler Universitätsklinikum GmbH- Med. Campus III Linz, Austria
  • Ordensklinikum Linz - Elisabethinen Linz, Austria
View all 77 locations
View Trial Details
Completed

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

NCT03484702

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Local Institution - 101 Vienna, Austria
  • Local Institution - 351 Ghent, Belgium
  • Local Institution - 551 Helsinki, Finland
  • Local Institution - 202 Lille, France
View all 20 locations
View Trial Details
Completed

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT04434196

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +16 more
Locations
  • Local Institution - 106 Boston, Massachusetts, United States
  • Local Institution - 104 Columbus, Ohio, United States
  • Local Institution - 101 Portland, Oregon, United States
  • Local Institution - 107 Dallas, Texas, United States
View all 15 locations
View Trial Details
Completed

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

NCT01660451

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations
  • Birmingham, Alabama, United States
  • Gilbert, Arizona, United States
  • Anaheim, California, United States
  • Aurora, Colorado, United States
View all 102 locations
View Trial Details

Related conditions